A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Clinical trial NCT04209114 · COMPLETED

Trial details

NCT number: NCT04209114
Sponsor: Bristol-Myers Squibb
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Bladder Cancer Bladder Tumor Muscle-Invasive Bladder Cancer

Start date: 2020-02-05
Primary completion: 2023-06-07
Enrollment: 114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.